Agendia Receives ?1.27 Million in Funding from the EU's Seventh Framework Programme

Irvine, California and Amsterdam (ots/PRNewswire) -

- Company Will Develop Companion Diagnostics With Consortiums of
Leading European Cancer Centers and Translational Research Groups

Agendia, a global innovator in molecular cancer diagnostics,
announced today that, together with thought-leading collaborators in
clinical centers and translational research groups, it has launched
the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon
Cancer and Therapeutics) consortiums. The partnerships will
collectively receive nearly EUR12 million in funding from the
European Union's 7th Framework Programme over a five-year term.
Agendia, in particular, will receive EUR1.27 million for the
development of new molecular diagnostics to help guide individualized
treatment of cancer patients.

Both consortiums will be focused on gaining deeper insight into
molecular subtypes of breast and colon cancer, and the development of
biomarkers for use in predicting patients' individual responses to
new targeted drugs. While RATHER seeks to improve treatment for
triple negative and lobular breast cancer patients, COLTHERES is
focused on response or resistance to targeted therapeutics in colon
cancer. Both consortiums consist of clinical partners as well as
leading translational research groups with a proven track record in
developing companion diagnostics for cancer therapies. The objective
of these partnerships is to define and perform biomarker-driven
clinical trials to improve cancer therapy outcomes, with Agendia
developing reliable and standardized biomarker tests.

Other members of the consortiums include the University College
Dublin, the Netherlands Cancer Institute (NKI) Amsterdam, Institute
Curie Paris, Malmö University Hospital Lund, Vall d'Hebron Barcelona,
University of Cambridge, OncoMark Ltd Dublin, University of Leuven,
Niguarda Ca' Granda Hospital Milano, IDIBELL Barcelona, Horizon
Discovery UK, University of Liverpool, Swiss Institute of
Bioinformatics and the University of Torino School of Medicine.

"We are pleased to participate in these EU funded projects and to
work with these outstanding international experts in the fields of
functional genomics, pharmacogenetics, bio-informatics and clinical
oncology," said Prof. Dr. Rene Bernards, CSO of Agendia. "For
Agendia, this is a great opportunity to develop new companion
diagnostics together with a large group of scientists and physicians
to address urgent clinical needs. The unique consortium structures
will allow a rapid translation of results from research and discovery
into a clinical setting that benefits patients."

About Agendia:

Agendia [http://www.agendia.com ] is a leading global commercial
molecular diagnostic company that develops and markets genomic-based
diagnostic products that improve the quality of life for cancer
patients and simplifies complex treatment decisions for their
physicians. Agendia's Symphony(TM) suite of breast cancer products
is based on the analysis of hundreds of genes in a patient's breast
and provides unprecedented biological insight to address complex
treatment decisions. Symphony(TM) includes MammaPrint(R), the first
and only FDA-cleared IVDMIA breast cancer recurrence assay, as well
as BluePrint(R), a molecular subtyping assay, TargetPrint(R), an
ER/PR/HER2 expression assay, and TheraPrint(R), a therapy selection
assay. Together, these tests help physicians determine a patient's
individual risk for metastasis, which patients will benefit from
chemo or hormonal therapy, and who can instead be treated with other
less arduous and costly methods.

In addition to the Symphony(TM) suite of tests, Agendia has a
rich pipeline of genomic products in development based on its
world-class genomic platform. The company also collaborates with
pharmaceutical companies to develop companion diagnostic tests in the
area of oncology and is a critical partner in the ISPY-2 and MINDACT
trials.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Amsterdam, the Netherlands, and
Irvine, California, United States. For more information, please visit
http://www.agendia.com.

For more information on COLTHERES consortium go to
http://www.coltheres.eu/. For more information on the RATHER Project
go to http://www.ratherproject.com/.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information, please contact: International media
andinvestor inquiries, M:Communications, Peter Laing / Amber
Bielecka, Tel:+44(0)20-7920-2352, E-mail: Agendia@mcomgroup.com; US
media inquiries,Ricochet Public Relations, Valerie Carter, Tel:
+1-202-316-0143, E-mail:vcarter@ricochetpr.com